1. Home
  2. AVTX vs QNCX Comparison

AVTX vs QNCX Comparison

Compare AVTX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVTX
  • QNCX
  • Stock Information
  • Founded
  • AVTX 2011
  • QNCX 2012
  • Country
  • AVTX United States
  • QNCX United States
  • Employees
  • AVTX N/A
  • QNCX N/A
  • Industry
  • AVTX Biotechnology: Pharmaceutical Preparations
  • QNCX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • AVTX Health Care
  • QNCX Health Care
  • Exchange
  • AVTX Nasdaq
  • QNCX Nasdaq
  • Market Cap
  • AVTX 88.4M
  • QNCX 62.0M
  • IPO Year
  • AVTX 2015
  • QNCX 2019
  • Fundamental
  • Price
  • AVTX $7.35
  • QNCX $1.40
  • Analyst Decision
  • AVTX Strong Buy
  • QNCX Strong Buy
  • Analyst Count
  • AVTX 4
  • QNCX 4
  • Target Price
  • AVTX $33.00
  • QNCX $9.50
  • AVG Volume (30 Days)
  • AVTX 54.4K
  • QNCX 126.6K
  • Earning Date
  • AVTX 03-28-2025
  • QNCX 03-31-2025
  • Dividend Yield
  • AVTX N/A
  • QNCX N/A
  • EPS Growth
  • AVTX N/A
  • QNCX N/A
  • EPS
  • AVTX N/A
  • QNCX N/A
  • Revenue
  • AVTX $820,000.00
  • QNCX N/A
  • Revenue This Year
  • AVTX N/A
  • QNCX N/A
  • Revenue Next Year
  • AVTX N/A
  • QNCX N/A
  • P/E Ratio
  • AVTX N/A
  • QNCX N/A
  • Revenue Growth
  • AVTX N/A
  • QNCX N/A
  • 52 Week Low
  • AVTX $4.18
  • QNCX $0.51
  • 52 Week High
  • AVTX $34.46
  • QNCX $2.45
  • Technical
  • Relative Strength Index (RSI)
  • AVTX 42.79
  • QNCX 36.52
  • Support Level
  • AVTX $7.42
  • QNCX $1.38
  • Resistance Level
  • AVTX $8.50
  • QNCX $1.49
  • Average True Range (ATR)
  • AVTX 0.64
  • QNCX 0.12
  • MACD
  • AVTX 0.02
  • QNCX -0.01
  • Stochastic Oscillator
  • AVTX 17.16
  • QNCX 7.32

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Share on Social Networks: